293 related articles for article (PubMed ID: 24794028)
1. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011).
Sineshaw HM; Gaudet M; Ward EM; Flanders WD; Desantis C; Lin CC; Jemal A
Breast Cancer Res Treat; 2014 Jun; 145(3):753-63. PubMed ID: 24794028
[TBL] [Abstract][Full Text] [Related]
2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
[TBL] [Abstract][Full Text] [Related]
3. Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010.
Parise CA; Caggiano V
BMC Cancer; 2013 Oct; 13():449. PubMed ID: 24083624
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
5. Socioeconomic disparities and breast cancer hormone receptor status.
Andaya AA; Enewold L; Horner MJ; Jatoi I; Shriver CD; Zhu K
Cancer Causes Control; 2012 Jun; 23(6):951-8. PubMed ID: 22527173
[TBL] [Abstract][Full Text] [Related]
6. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
7. HER2 status and disparities in luminal breast cancers.
Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
[TBL] [Abstract][Full Text] [Related]
8. Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status.
Tannenbaum SL; Koru-Sengul T; Zhao W; Miao F; Byrne MM
Cancer J; 2014; 20(4):237-45. PubMed ID: 25098282
[TBL] [Abstract][Full Text] [Related]
9. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.
Li CI; Malone KE; Daling JR
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):601-7. PubMed ID: 12101106
[TBL] [Abstract][Full Text] [Related]
10. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
11. Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 May; 163(1):151-158. PubMed ID: 28213780
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
13. Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women.
Linnenbringer E; Geronimus AT; Davis KL; Bound J; Ellis L; Gomez SL
Breast Cancer Res Treat; 2020 Apr; 180(2):437-447. PubMed ID: 32002766
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
Cerne JZ; Ferk P; Frkovic-Grazio S; Leskosek B; Gersak K
Climacteric; 2012 Feb; 15(1):68-74. PubMed ID: 22132797
[TBL] [Abstract][Full Text] [Related]
15. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California.
Banegas MP; Tao L; Altekruse S; Anderson WF; John EM; Clarke CA; Gomez SL
Breast Cancer Res Treat; 2014 Apr; 144(3):625-34. PubMed ID: 24658879
[TBL] [Abstract][Full Text] [Related]
18. Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
Akinyemiju T; Moore JX; Ojesina AI; Waterbor JW; Altekruse SF
Breast Cancer Res Treat; 2016 Jun; 157(3):575-86. PubMed ID: 27255533
[TBL] [Abstract][Full Text] [Related]
19. Racial and ethnic disparities in the diagnosis of breast cancer: changes in presenting stage in minority populations in Florida during 1981-2009.
Dosch AR; Koru-Sengul T; Miao F; Tannenbaum SL; Byrne MM; Wright JL
Breast Cancer Res Treat; 2014 Nov; 148(2):379-87. PubMed ID: 25301087
[TBL] [Abstract][Full Text] [Related]
20. Racial/ethnic differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: Findings from ten National Program of Cancer Registries states.
Zhang L; King J; Wu XC; Hsieh MC; Chen VW; Yu Q; Fontham E; Loch M; Pollack LA; Ferguson T
Cancer Epidemiol; 2019 Feb; 58():1-7. PubMed ID: 30415099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
